Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB has released its interim report for January to September 2025, highlighting its ongoing efforts in developing targeted therapies for critical diseases. The report underscores the company’s strategic advancements and partnerships, which are pivotal in enhancing its market position and providing potential benefits to stakeholders.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia is a Swedish biotech company that develops targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases. The company’s drug candidates aim to provide new and improved treatments for serious and debilitating conditions.
Average Trading Volume: 2,891,486
Technical Sentiment Signal: Buy
Current Market Cap: SEK892.5M
See more data about CANTA stock on TipRanks’ Stock Analysis page.